# EDGAR Filing Document

**Accession Number:** 0001878313
**File Stem:** 0001493152-26-019015
**Filing Date:** 2026-4
**Character Count:** 4954
**Document Hash:** 199dcd922b7e2d66481a2c2cecdf48f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-019015.hdr.sgml**: 20260427

**ACCESSION NUMBER**: 0001493152-26-019015

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260427

**DATE AS OF CHANGE**: 20260427

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAIA Biotechnology, Inc.
- **CENTRAL INDEX KEY:** 0001878313
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41455
- **FILM NUMBER:** 26896378

**BUSINESS ADDRESS:**
- **STREET 1:** 444 WEST LAKE STREET, SUITE 1700
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606
- **BUSINESS PHONE:** 312-416-8592

**MAIL ADDRESS:**
- **STREET 1:** 444 WEST LAKE STREET, SUITE 1700
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

**<u>MAIA Biotechnology, Inc.</u>**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

**Payment of Filing Fee (Check all boxes that apply):**

☒ No fee required

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

**MAIA Biotechnology, Inc.**

**Amendment and Supplement to the Proxy Statement**

**For the Annual Meeting of Stockholders**

**To be Held on May 21, 2026**

**EXPLANATORY NOTE**

On April 7, 2026, MAIA Biotechnology, Inc. ("MAIA" or the "Company") filed its definitive proxy statement (the "Proxy Statement") with the Securities and Exchange Commission ("SEC") for its annual meeting of shareholders to be held on May 21, 2026 (the "Annual Meeting").

The Company is amending and supplementing the Proxy Statement with the information provided in this amendment and supplement to the Proxy Statement (the "Amendment and Supplement") to include information related to "Securities Authorized for Issuance Under Equity Compensation Plans" which was inadvertently omitted from the Proxy Statement.

**Any proxies submitted by stockholders before the date of this Amendment and Supplement will be voted as instructed on those proxies, unless a stockholder changes his or her vote by submitting a later dated proxy. Stockholders should follow the instructions described in the Proxy Statement regarding how to submit proxies or vote at the Annual Meeting.**

**THIS AMENDMENT AND SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.**

*This supplemental information should be read in conjunction with the Proxy Statement, which should be read in its entirety. Section references in the below disclosures are to sections in the Proxy Statement, and defined terms used but not defined herein have the meanings set forth in the Proxy Statement. To the extent the following information differs from or conflicts with the information contained in the Proxy Statement, the information set forth below shall be deemed to supersede the respective information in the Proxy Statement.*

**Amendments and Supplemental Disclosure**

**<u>Proxy Statement</u>**

The table below entitled "Securities Authorized for Issuance Under Equity Compensation Plans" is inserted into the Proxy Statement immediately following the section entitled "SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT": as follows:

**Securities Authorized for Issuance Under Equity Compensation Plans**

The following table summarizes information about our equity compensation plans as of December 31, 2025.

---

| | | | |
|:---|:---|:---|:---|
| **Plan Category** | **Number of**<br> **securities to**<br> **be issued upon**<br> **exercise**<br> **of outstanding**<br> **options,**<br> **warrants and**<br> **rights**<br> **(a)** | **Weighted**<br> **average**<br> **exercise price of**<br> **outstanding**<br> **options,**<br> **warrants and**<br> **rights** | **Number of**<br> **securities**<br> **remaining**<br> **available for future**<br> **issuance under**<br> **equity**<br> **compensation plans**<br> **(excluding**<br> **securities reflected**<br> **in**<br> **column (a))**  |
| Equity compensation plans approved by security holder | 25964.601 | $2.05 | 431153 |
| Equity compensation plans not approved by security holder | - | - | - |
| Total | 25964601 | $2.05 | 431153 |

---